文献速递甲状腺与浅表头颈介入US

微波消融治疗低风险甲状腺乳头状微小癌的安全性和有效性:一项前瞻性多中心研究

Safety and efficacy of microwave ablation for the treatment of low-risk papillary thyroid microcarcinoma: a prospective multicenter study.
PubMed 文献 · Eur Radiol · 2023-06-09

该前瞻性多中心研究于2017年1月至2021年6月筛查低风险甲状腺乳头状微小癌患者,对接受热消融者行超声引导下微波消融,共纳入1278例,平均随访34.57±28.98个月,36个月时6例出现局部肿瘤进展,中央区淋巴结转移率0.39%至0.78%,总并发症率1.41%,结论认为热消融安全有效,可能有助于填补手术与主动监测之间的治疗选择空白。

要点

  • 低风险甲状腺乳头状微小癌行超声引导下微波消融,局部麻醉下操作时间30.21±5.14分钟。
  • 平均随访34.57±28.98个月,36个月局部肿瘤进展6例,中央区淋巴结转移率0.78%。
  • 总并发症率1.41%,声音嘶哑发生率1.10%,均在6个月内恢复。

核心结论

  • 观察显示低风险甲状腺乳头状微小癌的热消融安全有效,并发症少且轻微;该技术可能有助于填补手术与主动监测之间的治疗选择空白,使希望以微创方式处理甲状腺乳头状微小癌的患者多一种选择。

研究设计与样本

  • 前瞻性多中心研究,2017年1月至2021年6月筛查低风险甲状腺乳头状微小癌患者,讨论主动监测、手术和热消融的管理细节,接受热消融者行微波消融,共纳入1278例,主要结局为无病生存期,次要结局为肿瘤大小和体积变化、局部肿瘤进展、淋巴结转移和并发症率。

诊断标准与关键数值

  • 局部肿瘤进展:36个月时6例出现局部肿瘤进展,其中5例接受第二次消融,1例接受手术。
  • 中央区淋巴结转移率:6个月为0.39%,12个月为0.63%,36个月为0.78%。
  • 36个月时10例中央区淋巴结转移患者中,5例选择消融,3例选择手术,另2例选择主动监测。
  • 总并发症率为1.41%,1.10%的患者出现声音嘶哑,所有患者均在6个月内恢复。

临床应用与阅片要点

  • 本研究观察显示,超声引导下经皮微波消融治疗甲状腺乳头状微小癌是在局部麻醉下进行的微创治疗,操作时间短。
  • 本研究观察显示,微波消融治疗甲状腺乳头状微小癌的局部肿瘤进展率和并发症率很低。
  • 作者认为,该技术可能有助于填补手术与主动监测之间的治疗选择空白,使希望以微创方式处理甲状腺乳头状微小癌的患者多一种选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To assess the safety and efficacy of ultrasound-guided thermal ablation for low-risk papillary thyroid microcarcinoma (PTMC) via a prospective multicenter study.

METHODS: From January 2017 through June 2021, low-risk PTMC patients were screened. The management details of active surveillance (AS), surgery, and thermal ablation were discussed. Among patients who accepted thermal ablation, microwave ablation (MWA) was performed. The main outcome was disease-free survival (DFS). The secondary outcomes were tumor size and volume changes, local tumor progression (LTP), lymph node metastasis (LNM), and complication rate.

RESULTS: A total of 1278 patients were included in the study. The operation time of ablation was 30.21 ± 5.14 min with local anesthesia. The mean follow-up time was 34.57 ± 28.98 months. Six patients exhibited LTP at 36 months, of whom 5 patients underwent a second ablation, and 1 patient received surgery. The central LNM rate was 0.39% at 6 months, 0.63% at 12 months, and 0.78% at 36 months. Of the 10 patients with central LNM at 36 months, 5 patients chose ablation, 3 patients chose surgery and the other 2 patients chose AS. The overall complication rate was 1.41%, and 1.10% of patients developed hoarseness of the voice. All of the patients recovered within 6 months.

CONCLUSIONS: Thermal ablation of low-risk PTMC was observed to be safe and efficacious with few minor complications. This technique may help to bridge the gap between surgery and AS as treatment options for patients wishing to have their PTMC managed in a minimally invasive manner.

CLINICAL RELEVANCE STATEMENT: This study proved that microwave ablation is a safe and effective treatment method for papillary thyroid microcarcinoma.

KEY POINTS: Percutaneous US-guided microwave ablation of papillary thyroid microcarcinoma is a very minimally invasive treatment under local anesthesia during a short time period. The local tumor progression and complication rate of microwave ablation in the treatment of papillary thyroid microcarcinoma are very low.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Han, Dou, Zheng, et al. Safety and efficacy of microwave ablation for the treatment of low-risk papillary thyroid microcarcinoma: a prospective multicenter study. Eur Radiol. 2023. PMID: 37294329. doi:10.1007/s00330-023-09802-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。